NASDAQ:SGMO
Sangamo BioSciences Stock News
$0.561
+0.0380 (+7.26%)
At Close: May 10, 2024
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
10:00pm, Monday, 28'th Feb 2022 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: Cowen 42nd Annual Health Care Conference Date: Monday, March 7th at 12:50 p.m. Eastern Time Barclays Global Healthcare Conference Date: Thursday, March 17th at 9:00 a.m. Eastern Time H.C. Wainwright & Co. Gene Editing and Therapy Conference 2022 Date: Wednesday, March 30th at 7:00 a.m. Eastern T
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
05:00pm, Monday, 28'th Feb 2022
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences: C
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
02:27am, Friday, 25'th Feb 2022 Seeking AlphaSangamo Therapeutics rises 5% after hours following Q4 earnings
11:03pm, Thursday, 24'th Feb 2022 Seeking Alpha
Sangamo Therapeutics'' (SGMO) Q4 2021 beats on the top and bottom lines has propelled the stock 5% higher in after-hours trading.
Sangamo Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
09:40pm, Thursday, 24'th Feb 2022 Seeking AlphaSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
09:27pm, Thursday, 24'th Feb 2022
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2021 Results - Earnings Call Transcript
Sangamo Therapeutics GAAP EPS of -$0.26 beats by $0.09, revenue of $28M beats by $0.64M
09:02pm, Thursday, 24'th Feb 2022 Seeking Alpha
Sangamo Therapeutics press release (SGMO): Q4 GAAP EPS of -$0.26 beats by $0.09.Revenue of $28M (+8.5% Y/Y) beats by $0.64M.Cash, cash equivalents and marketable securities as…
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
09:01pm, Thursday, 24'th Feb 2022 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights. “In 2021, we continued to advance the development of genomic medicines for patients across multiple therapeutic areas using our innovative technologies,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We along with our partners presented compelling clinical data in our three lead pro
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
08:00pm, Thursday, 24'th Feb 2022
Sangamo (SGMO) delivered earnings and revenue surprises of 23.53% and 4.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics: Lost In Transition From Lab To Clinic
04:59pm, Thursday, 24'th Feb 2022 Seeking AlphaSangamo Therapeutics Q4 2021 Earnings Preview
10:35pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to announce Q4 earnings results on Thursday, Feb. 24, after market close.Consensus EPS estimate is -$0.34
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
09:30pm, Thursday, 17'th Feb 2022 Business Wire
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2021 financial results after the market closes on Thursday, February 24, 2022. The press release will be followed by a conference call at 4:30 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast
04:30pm, Thursday, 17'th Feb 2022
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year
After Sangamo Therapeutics Inc. (NASDAQ:SGMO) Fell -2.17% What Analysts Have Been Expecting
01:30pm, Friday, 11'th Feb 2022 Stocks Register
Sangamo Therapeutics Inc. (NASDAQ:SGMO) price on Thursday, February 10, fall -2.17% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $5.86. A look at the stock’s price movement, the close in the last trading session was $5.99, moving within a range at $5.755 and $6.27. The beta value … After Sangamo Therapeutics Inc. (NASDAQ:SGMO) Fell -2.17% What Analysts Have Been Expecting Read More »
Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight
06:00pm, Wednesday, 09'th Feb 2022 Benzinga
Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythematosus Pipeline analysis depicts a robust space with 70 + active players working to develop 70 + pipeline treatment therapies. Some of the key pharmaceutical companies working to develop potential drug candidates to improve the Systemic Lupus Erythematosus treatment scenario include AstraZeneca, Eli Lilly and Company, UCB Pharma, Hoffmann-La Roche, Biogen, ImmuPharma, Xencor, Bristol Myers Squibb, Kumming Pharmaceuticals, Alpine Immune Sciences, Sanofi, Momenta Pharmaceuticals, Pfizer, Idorsia Pharmaceuticals, Resolve Therapeutics, ILTOO Pharma, Amgen, AbbVie, Novartis, Corestem, Corbus Pharmaceuticals, Viela Bio, Janssen Biotech, Boston Pharmaceuticals, InnoCare Pharma, Kezar Life Sciences, Kangpu Biopharmaceuticals, ACEA therapeutics, Mitsubishi Tanabe Pharma Corporation, Janssen Research & Development, Landos Biopharma, Equillium, Merck Healthcare KGaA, Gilead sciences, I-Mab Biopharma, Biocon Limited, Nektar Therapeutics, Hoffman-La-Roche, Sangamo therapeutics, Araim Pharmaceuticals, Chipscreen Biosciences, AstraZeneca/BenevolentAI, Reistone Biopharma, OMass Therapeutics, and many others.